Skip to main content
  1. Home
  2. Emerging Tech
  3. News

SpaceX eyeing December 16 launch, its first since September explosion

Add as a preferred source on Google

After a severe setback in September when one of its rockets exploded on the launchpad, SpaceX may be just a couple of weeks from resuming its space missions.

Satellite manufacturer Iridium Communications said on Thursday that it plans to launch 10 satellites via a SpaceX Falcon 9 rocket on December 16. The mission is subject to approval by the Federal Aviation Administration (FAA), which is currently studying SpaceX’s findings on the September 1 explosion.

Recommended Videos

If the launch is green-lighted, it would be a major boost for the SpaceX team, which at one point was wondering if its rockets might be grounded for up to a whole year.

“Really surprising problem”

September’s fiery incident was put down to a fueling issue that SpaceX CEO recently described as a “really surprising problem that’s never been encountered before in the history of rocketry.” Musk added that solving it had been the company’s biggest challenge since its founding in 2002.

In an interview on NBC broadcast last month, the CEO said it appeared that liquid oxygen froze as it was flowing into the second stage tank, with the unexpected occurrence leading to the catastrophic failure.

The explosion resulted in the loss of not only a Falcon 9 rocket but also a $200-million Israeli satellite that Facebook was planning to use for its ongoing work to bring internet connectivity to remote parts of the world.

With contracts for future missions to ferry supplies to the International Space Station and take satellites into space, as well as far bolder goals that involve trips into deep space and even helping to build a city on Mars, SpaceX certainly can’t afford too many more failures like the one it suffered three months ago.

But before anything happens, we’ll have to wait and see if the FAA gives the go ahead for the proposed December 16 launch. If it does, it’ll be a very welcome early Christmas present for Musk and his SpaceX team.

Trevor Mogg
Contributing Editor
Not so many moons ago, Trevor moved from one tea-loving island nation that drives on the left (Britain) to another (Japan)…
Students who use AI every day may be falling behind, while moderate users pull ahead
New global testing data suggests more AI in the classroom isn't automatically better.
Logo, Text

I assumed more AI access might help students learn faster. However, a new OECD study dispels that misconception for me and everyone else who gave their children a paid version of AI chatbots, thinking it would help them through their educational journey. 

According to PISA 2025 data from 760,000 students in 91 countries, students who use AI daily score meaningfully worse on standardized tests than their peers. The full picture is more complicated than a simple ban would fix.

Read more
XPENG just put its humanoid robot on the production line, and it walked itself out
IRON clocks in for its first shift
XPENG Iron

XPENG’s humanoid robot has officially joined the workforce, and it even got an employee badge. The Chinese automaker announced on September 8 that its next-generation IRON had completed assembly and autonomously walked off its newly commissioned humanoid robot production line in Guangzhou.

CEO He Xiaopeng then pinned a staff badge onto the robot, symbolically welcoming it to the XPENG team. It is a charming little ceremony for a machine that the company hopes will eventually become a regular part of everyday life. XPENG is moving IRON beyond R&D prototypes toward production-line manufacturing, applying the quality-control systems and manufacturing experience it has developed through its electric vehicle business.

Read more
An AI-designed drug might help slow aging, but we’re not there yet
The results hint at a possible anti-aging effect, but there’s still a long way to go before we know what it means.
medical test tubes

Rentosertib, a drug Insilico Medicine designed almost entirely using AI, was created to treat idiopathic pulmonary fibrosis, a disease that scars and stiffens the lungs over time. But fighting lung disease was only half the plan from the start.

According to a new study published in Nature Biotechnology, the drug's target was chosen specifically because it overlaps heavily with the biology of aging, and the whole trial was designed to test whether treating the lungs could also mean turning back the body's biological clock.

Read more